Transcript Dronedarone in patients with congestive heart failure: insights from

Dronedarone in patients with congestive heart failure:
insights from ATHENA
by Stefan H. Hohnloser, Harry J.G.M. Crijns, Martin van Eickels, Christophe Gaudin,
Richard L. Page, Christian Torp-Pedersen, Stuart J. Connolly, and
EHJ
Volume 31(14):1717-1721
July 14, 2010
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author
2010. For permissions please email: [email protected]
Kaplan–Meier cumulative incidence curves of time to first cardiovascular hospitalization or
death in patients with NYHA II/III congestive heart failure and left ventricular ejection fraction
≤0.40 at baseline assigned to dronedarone or placebo.
Stefan H. Hohnloser et al. Eur Heart J 2010;31:1717-1721
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author
2010. For permissions please email: [email protected]
Forrest plot for first cardiovascular hospitalization or death in the overall ATHENA population
and patients with or without NYHA II/III congestive heart failure and left ventricular ejection
fraction ≤0.40 at baseline.
Stefan H. Hohnloser et al. Eur Heart J 2010;31:1717-1721
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author
2010. For permissions please email: [email protected]
Changes in serum creatinine concentration relative to baseline values during the course of the
study in patients with NYHA II/III congestive heart failure and left ventricular ejection fraction
≤0.40 at baseline assigned to dronedarone or placebo.
Stefan H. Hohnloser et al. Eur Heart J 2010;31:1717-1721
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author
2010. For permissions please email: [email protected]